AR050561A1 - Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos. - Google Patents
Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos.Info
- Publication number
- AR050561A1 AR050561A1 ARP050103727A ARP050103727A AR050561A1 AR 050561 A1 AR050561 A1 AR 050561A1 AR P050103727 A ARP050103727 A AR P050103727A AR P050103727 A ARP050103727 A AR P050103727A AR 050561 A1 AR050561 A1 AR 050561A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion proteins
- plasminogen activator
- plasminogen activating
- analogs
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Proteínas de fusion que comprenden una proteína de direccionamiento y una activador del plasminogeno, preferiblemente un anticuerpo que se une a una P-selectina, unido operativamente al activador del plasminogeno DSPAalfa1, o análogos, fragmentos, derivados o variantes de éstas, que son utiles como agentes trombolíticos. También se describen composiciones farmacéuticas que contienen estas proteínas de fusion, métodos para usar estas proteínas de fusion como agentes trombolíticos y procesos para sintetizar estas proteínas de fusion. Reivindicacion 1: Una proteína de fusion trombolítica caracterizada porque comprende una proteína de direccionamiento, que se une a una estructura biologica relacionada con el dano vascular, que está unida operativamente a un activador de plasminogeno, o análogos, fragmentos, derivados o variantes de ésta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005061685A JP2006241109A (ja) | 2005-03-04 | 2005-03-04 | ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050561A1 true AR050561A1 (es) | 2006-11-01 |
Family
ID=36146922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103727A AR050561A1 (es) | 2005-03-04 | 2005-09-06 | Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090286721A1 (es) |
| EP (1) | EP1863910A1 (es) |
| JP (2) | JP2006241109A (es) |
| CN (1) | CN101155916A (es) |
| AR (1) | AR050561A1 (es) |
| CA (1) | CA2601271A1 (es) |
| MY (1) | MY154979A (es) |
| RU (1) | RU2007136791A (es) |
| WO (1) | WO2006094536A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101109012B (zh) * | 2007-07-16 | 2013-04-10 | 刘德虎 | 吸血蝙蝠纤溶酶原激活剂α2在酵母中的表达及生产方法 |
| CN101748110B (zh) * | 2008-12-01 | 2012-06-06 | 齐鲁制药有限公司 | 去氨普酶α1突变体 |
| CN103966173B (zh) * | 2014-05-04 | 2017-02-01 | 苏州大学 | 一种杂交瘤细胞及其产生的单克隆抗体和应用 |
| CA2966332C (en) | 2014-11-03 | 2024-04-16 | Thrombolytic Science, Llc | Methods and compositions for safe and effective thrombolysis |
| KR20180117102A (ko) * | 2016-01-08 | 2018-10-26 | 바이오얼라이언스 씨.브이. | 사가 항-psgl-1 항체 및 이들의 용도 |
| WO2018232305A1 (en) * | 2017-06-16 | 2018-12-20 | Thrombolytic Science, Llc | Methods and compositions for thrombolysis |
| EP3773665A1 (en) * | 2018-03-27 | 2021-02-17 | UMC Utrecht Holding B.V. | Targeted thrombolysis for treatment of microvascular thrombosis |
| WO2024060167A1 (zh) * | 2022-09-23 | 2024-03-28 | 庄伟哲 | 靶向整合素αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188522C (zh) * | 2001-07-20 | 2005-02-09 | 健力福生化技术（上海）有限公司 | 一种血栓靶向性溶栓蛋白表达质粒及其构建 |
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
-
2005
- 2005-03-04 JP JP2005061685A patent/JP2006241109A/ja active Pending
- 2005-09-02 MY MYPI20054125A patent/MY154979A/en unknown
- 2005-09-06 CA CA002601271A patent/CA2601271A1/en not_active Abandoned
- 2005-09-06 RU RU2007136791/13A patent/RU2007136791A/ru not_active Application Discontinuation
- 2005-09-06 EP EP05787488A patent/EP1863910A1/en not_active Withdrawn
- 2005-09-06 CN CNA2005800493718A patent/CN101155916A/zh active Pending
- 2005-09-06 JP JP2007557335A patent/JP2008531023A/ja not_active Withdrawn
- 2005-09-06 AR ARP050103727A patent/AR050561A1/es not_active Application Discontinuation
- 2005-09-06 WO PCT/EP2005/009553 patent/WO2006094536A1/en active Application Filing
- 2005-09-06 US US11/817,454 patent/US20090286721A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY154979A (en) | 2015-08-28 |
| EP1863910A1 (en) | 2007-12-12 |
| WO2006094536A1 (en) | 2006-09-14 |
| CN101155916A (zh) | 2008-04-02 |
| CA2601271A1 (en) | 2006-09-14 |
| JP2008531023A (ja) | 2008-08-14 |
| RU2007136791A (ru) | 2009-04-10 |
| JP2006241109A (ja) | 2006-09-14 |
| US20090286721A1 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050561A1 (es) | Proteinas de fusion activadoras del plasminogeno como agentes tromboliticos. | |
| AR119287A2 (es) | Composición que comprende una molécula de factor viii unida a un polímero hidrosoluble | |
| EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| PE20081610A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos | |
| CL2011003122A1 (es) | Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer. | |
| EA200801571A1 (ru) | Композиции, содержащие молекулы ctl4-ig, и способы их получения | |
| PE20081506A1 (es) | Formulaciones de ansamicina | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| BRPI0514340A (pt) | formulações de estabilização | |
| ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
| CY1115078T1 (el) | Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| EA200870164A1 (ru) | Лечение вирусного гепатита | |
| DE602005020611D1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| EA200800514A1 (ru) | Замещённые 7-азаиндазолы, содержащие их композиции, способ получения и применения | |
| EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
| AR059257A1 (es) | Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos | |
| EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
| EA200600065A2 (ru) | Гидрофобные композиционные и сыпучие материалы, их применение | |
| NO20064866L (no) | IRTA-5 antistoffer og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |